Email this article EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION
- Authors: Sherman N.Z.1, Ramazanova M.S.2, Gopachenko Y.N.1
-
Affiliations:
- Department of Chemotherapy, Kirov Regional Clinical Oncology Dispensary
- Department of Oncology, Kirov State Medical Academy, Ministry of Health of Russia
- Issue: Vol 3, No 4 (2014)
- Pages: 27-31
- Section: ORIGINAL REPORTS
- Published: 01.03.2015
- URL: https://onco-surgery.info/jour/article/view/86
- DOI: https://doi.org/10.17650/2220-3478-2014-0-4-27-31
- ID: 86
Cite item
Full Text
Abstract
Purpose. To conduct retrospective analysis of treatment results of combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab use in Kirov regional clinical oncology dispensary.
Materials and methods. The study was conducted in Kirov regional clinical oncology dispensary from 2008 until 2014. 35 patients treated with combined first line therapy including bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab were retrospectively evaluated. Overall response was evaluated using RECIST ver. 1.1 criteria. Long term outcomes – progression free and overall survival were evaluated. Treatment safety was evaluated using NCI CTCAE.
Results. There were no complete remissions in second line bevacizumab treatment, partial remissions were detected for 4 (22.2 %) patients, stable disease for 14 (77.8 %). Median progression free survival in both groups was comparable 9.1 and 10.4 months respectively. Patients treated with bevacizumab in first and second lines of treatment had 8.2 months survival benefit (p > 0.05).
Conclusions. Combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with bevacizumab improves overall survival on 8.2 months in comparison with patients who stopped bevacizumab treatment after first disease progression.
About the authors
N. Z. Sherman
Department of Chemotherapy, Kirov Regional Clinical Oncology Dispensary
Author for correspondence.
Email: chemotherapy@list.ru
Russian Federation
M. S. Ramazanova
Department of Oncology, Kirov State Medical Academy, Ministry of Health of Russia
Email: chemotherapy@list.ru
Russian Federation
Ye. N. Gopachenko
Department of Chemotherapy, Kirov Regional Clinical Oncology Dispensary
Email: chemotherapy@list.ru
Russian Federation
References
Supplementary files
